SCHEMBL1264951

SCHEMBL1264951

N#CCC1CC=CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14535831 0.88
SCHEMBL1265827 0.83
SCHEMBL6412835 0.78 HSD17B10 (0.32)
Trimethylammonium SCHEMBL27395135 0.74
SCHEMBL18686399 0.74 KDM4E (0.31)
SCHEMBL5586074 0.74 KDM4E (0.34)
SCHEMBL18632113 0.73
SCHEMBL2138361 0.72 ALDH1A1 (0.39)
SCHEMBL17580303 0.72 ALDH1A1 (0.39)
Water SCHEMBL28778494 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124806-B2 Contrast agents GE HEALTHCARE AS (NO) 2012-02-28 US disclosed
US-8124806-B2 Contrast agents GE HEALTHCARE AS (NO) 2012-02-28 US disclosed
US-7880017-B2 Made by reacting a cyano compound with a silylalkylisocyanide compound; silylimidazole ; ALLERGAN, INC. (US) 2011-02-01 US disclosed
US-7880017-B2 Made by reacting a cyano compound with a silylalkylisocyanide compound; silylimidazole ; ALLERGAN, INC. (US) 2011-02-01 US disclosed
US-7880017-B2 Made by reacting a cyano compound with a silylalkylisocyanide compound; silylimidazole ; ALLERGAN, INC. (US) 2011-02-01 US disclosed
US-7598394-B2 Process for the synthesis of imidazoles ALLERGAN, INC. (US) 2009-10-06 US disclosed
US-7598394-B2 Process for the synthesis of imidazoles ALLERGAN, INC. (US) 2009-10-06 US disclosed
US-7598394-B2 Process for the synthesis of imidazoles ALLERGAN, INC. (US) 2009-10-06 US disclosed
US-20090053142-A1 CONTRAST AGENTS WYNN DUNCAN 2009-02-26 US disclosed
US-20090053142-A1 CONTRAST AGENTS WYNN DUNCAN 2009-02-26 US disclosed
US-7183305-B2 Process for the synthesis of imidazoles ALLERGAN, INC. (US) 2007-02-27 US disclosed
US-7183305-B2 Process for the synthesis of imidazoles ALLERGAN, INC. (US) 2007-02-27 US disclosed
US-7183305-B2 Process for the synthesis of imidazoles ALLERGAN, INC. (US) 2007-02-27 US disclosed
EP-1682517-A1 PROCESS FOR THE SYNTHESIS OF IMIDAZOLES Allergan, Inc. (US) 2006-07-26 EP disclosed
WO-2005047267-A1 PROCESS FOR THE SYNTHESIS OF IMIDAZOLES ALLERGAN, INC. (US) 2005-05-26 WO disclosed
US-20050101785-A1 Process for the synthesis of imidazoles ALLERGAN, INC. 2005-05-12 US disclosed
EP-0500653-A4 INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE BIOCRYST INC (US) 1995-08-23 EP disclosed
EP-0500653-A1 INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE BIOCRYST PHARMACEUTICALS INC. (US) 1992-09-02 EP disclosed
WO-1991006548-A1 INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE BIOCRYST, INC. (US) 1991-05-16 WO disclosed
US-4985434-A 7-substituted derivatives of 2-amino-3H,5H-pyrrolo(3,2-d)pyrimidin-4-ones and pharamceutical uses and compositions containing the same BIOCRYST, INC. (US) 1991-01-15 US disclosed